These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12523894)

  • 1. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
    Lairson DR; Begley CE; Reynolds TF; Wilhelmus KR
    Arch Ophthalmol; 2003 Jan; 121(1):108-12. PubMed ID: 12523894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group.
    Arch Ophthalmol; 2000 Aug; 118(8):1030-6. PubMed ID: 10922194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.
    N Engl J Med; 1998 Jul; 339(5):300-6. PubMed ID: 9696640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral antiviral prophylaxis in preventing ocular herpes simplex virus recurrences in patients with and without self-reported atopy.
    Rezende RA; Bisol T; Hammersmith K; Rapuano CJ; Lima AL; Webster GF; Freitas JF; Laibson PR; Cohen EJ
    Am J Ophthalmol; 2006 Oct; 142(4):563-7. PubMed ID: 17011845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group.
    Cornea; 2001 Mar; 20(2):123-8. PubMed ID: 11248812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.
    Asbell PA
    Trans Am Ophthalmol Soc; 2000; 98():285-303. PubMed ID: 11190029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis.
    Young RC; Hodge DO; Liesegang TJ; Baratz KH
    Arch Ophthalmol; 2010 Sep; 128(9):1178-83. PubMed ID: 20837803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.
    van Velzen M; van de Vijver DA; van Loenen FB; Osterhaus AD; Remeijer L; Verjans GM
    J Infect Dis; 2013 Nov; 208(9):1359-65. PubMed ID: 23901090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis].
    Shimomura Y
    Nippon Ganka Gakkai Zasshi; 2008 Mar; 112(3):247-64; discussion 265. PubMed ID: 18411713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyclovir for the treatment and prevention of recurrent infectious herpes simplex keratitis.
    Wu X; Chen X
    Chin Med J (Engl); 2002 Oct; 115(10):1569-72. PubMed ID: 12490113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.
    Miserocchi E; Modorati G; Galli L; Rama P
    Am J Ophthalmol; 2007 Oct; 144(4):547-51. PubMed ID: 17692271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy.
    Scott LL; Alexander J
    Am J Perinatol; 1998 Jan; 15(1):57-62. PubMed ID: 9475690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group.
    Wilhelmus KR; Dawson CR; Barron BA; Bacchetti P; Gee L; Jones DB; Kaufman HE; Sugar J; Hyndiuk RA; Laibson PR; Stulting RD; Asbell PA
    Br J Ophthalmol; 1996 Nov; 80(11):969-72. PubMed ID: 8976723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection.
    Uchoa UB; Rezende RA; Carrasco MA; Rapuano CJ; Laibson PR; Cohen EJ
    Arch Ophthalmol; 2003 Dec; 121(12):1702-4. PubMed ID: 14662588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections.
    Sudesh S; Laibson PR
    Curr Opin Ophthalmol; 1999 Aug; 10(4):230-3. PubMed ID: 10621528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group.
    Arch Ophthalmol; 1997 Jun; 115(6):703-12. PubMed ID: 9194719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group.
    Arch Ophthalmol; 1996 Sep; 114(9):1065-72. PubMed ID: 8790090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
    Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
    Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis.
    Randolph AG; Hartshorn RM; Washington AE
    Obstet Gynecol; 1996 Oct; 88(4 Pt 1):603-10. PubMed ID: 8841227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.